Colgate-Palmolive (CL) financials
NYSE · Consumer Defensive · Household & Personal Products · 33,600 employees · CEO Noel R. Wallace
- Price
- $95.29 +2.29%
- Market cap
- $76B
- Enterprise value
- $82.2B
- Last report
- Q3 '26 filed 2026-10-30
- Next report
- 2027-01-29 EPS est. $0.97
Revenue (TTM)$21.3B+5.9% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)20.5%-1.1 pp vs a year agoOperating income $4.37B
Net income (TTM)$2.05B-29.4% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)$3.79B+10.0% vs a year agoCapex $577M
Diluted EPS (TTM)$2.55-28.5% vs a year agoSum of the last 4 quarters
Net cash-$6.19B+10.9% vs a year agoCash + short-term investments - debt
Valuation & key figures
- Market cap
- $76B EV $82.2B
- Revenue
- $21.3B Trailing 12 months
- Revenue growth
- +5% FY2026 consensus
- Profit margin
- 9.6% Net income / revenue, TTM
- P/E
- 37.0× Forward 24.6× (FY2026)
- P/S
- 3.6× Price / sales, TTM
- EV / EBITDA
- 21.3× TTM
- Free cash flow
- $3.79B Trailing 12 months
- Net income
- $2.05B Trailing 12 months
- Revenue estimate
- $21.4B FY2026 consensus
- Earnings
- 2027-01-29 Revenue est. $5.37B
- Dividend
- $2.11 Per share, last 12 months
Key takeaways
Computed from the reported numbers - every statement carries the figure it rests on.
- Last report (2026-10-30): revenue beat by 0.6%, EPS beat by 4.8%Revenue $5.37B vs $5.34B expected (+0.6%); EPS $0.97 vs $0.93 (+4.8%).
- Revenue growth steady: 4.6% year on yearQ3 '26 revenue $5.37B, against an average of 5.3% over the four quarters before.
- Operating margin 20.5% (TTM), -1.1 pp on a year agoOperating income grew 0.6% while revenue grew 5.9%.
- 47.3% of pre-tax profit is eaten by non-operating lossesPre-tax income $2.97B vs operating income $4.37B (TTM). Losses on equity stakes and other one-off items cut net income and EPS - operating income is the cleaner measure of the business.
- Capex 2.7% of revenue (a year ago 2.8%)$577M invested in the last 4 quarters (+1.1% on a year earlier). Free cash flow $3.79B = 184.6% of net income.
- Returned $2.24B to shareholders = 59.0% of free cash flowBuybacks $406M (a year earlier $1.26B), dividends $1.83B, stock-based pay $141M (TTM).
- Diluted share count down 1.4% in a year799M diluted shares in Q3 '26, 810M a year earlier.
- Net debt $6.19BCash + short-term investments $1.53B, debt incl. leases $7.72B; a year ago net debt $6.95B.
Last quarter: Q3 '26
Quarter ended 2026-09-30. Compared with the same quarter a year earlier and with the analyst consensus before the report.
Quarter vs a year ago
| Q3 '26 | Year ago | Change | |
|---|---|---|---|
| Revenue | $5.37B | $5.13B | +4.6% |
| Gross margin | 60.2% | 59.4% | +0.8 pp |
| Operating income | $1.12B | $1.1B | +2.3% |
| Operating margin | 20.9% | 21.4% | -0.5 pp |
| Net income | $751M | $735M | +2.2% |
| Diluted EPS | $0.94 | $0.91 | +3.3% |
| Operating cash flow | $1.17B | $1.26B | -7.1% |
| Capex | $134M | $155M | -13.5% |
| Free cash flow | $1.04B | $1.11B | -6.2% |
| R&D | $0 | $0 | – |
| Stock-based compensation | $103M | $72M | +43.1% |
Reported vs consensus
2026-10-30| Actual | Consensus | vs consensus | |
|---|---|---|---|
| Revenue | $5.37B | $5.34B | +0.6% |
| EPS (as estimated) | $0.97 | $0.93 | +4.8% |
From the report of 2026-10-30 for Q3 '26: revenue and the EPS analysts estimate (often adjusted), so it can differ from the EPS of the statements above.
EPS vs consensus
last 8 reportsRevenue
Where the money comes from - by business line and by region, quarter by quarter.
Revenue, operating income and growth
quarterlyRevenue by business line
stacked, quarterly| Segment | Q3 '26 | y/y | Share | TTM | TTM y/y | 12 quarters |
|---|---|---|---|---|---|---|
| Oral, Personal and Home Care | $4.16B | +4.4% | 100.0% | – | – | |
| Pet Nutrition | – | – | – | – | – | |
| Hill's Pet Nutrition | – | – | – | – | – |
Revenue by region
share of total| Segment | Q3 '26 | y/y | Share | TTM | TTM y/y | 12 quarters |
|---|---|---|---|---|---|---|
| Oral, Personal and Home Care | $1.33B | +12.6% | 100.0% | – | – |
Segment profits
Operating income per reported segment, read from the segment note of each 10-Q / 10-K (the profit split most data feeds leave out).
Segments in Q3 '26
| Segment | Revenue | y/y | Operating income | y/y | Margin | Margin a year ago | TTM operating income |
|---|---|---|---|---|---|---|---|
| Oral Personal And Home Care | – | – | $1.04B | +5.0% | – | – | $4.15B |
| Pet Nutrition | – | – | – | – | – | – | – |
| Corporate (unallocated) | – | – | -$221M | -16.9% | – | – | -$2.1B |
| Hills Pet Nutrition | – | – | $267M | +4.7% | – | – | – |
Operating income by segment
quarterlySegment operating margin
quarterlyFourth quarters are derived: the 10-K reports the full year, minus the three quarters of the 10-Qs.
Margins & cost structure
How much of each unit of revenue is left at each level - and where the costs go.
Margins
quarterlyCosts as % of revenue
quarterlyCash flow & capital allocation
Cash generated, what it is spent on, and what reaches shareholders.
Operating cash flow, capex, free cash flow
quarterlyUses of cash vs operating cash flow
fiscal yearsLast 4 quarters
cash flow statement- Operating cash flow
- $4.37B
- Capex
- -$577M
- Buybacks
- -$406M
- Dividends
- -$1.83B
- Acquisitions
- $0
- Net debt issued
- -$577M
- Stock-based compensation
- $141M
- Free cash flow
- $3.79B
- Returned to shareholders / FCF
- 59.0%
Share count and EPS
quarterly, dilutedBalance sheet
Liquidity, investments and debt at each quarter end.
Cash, investments and debt
quarter endsValuation & returns
Today's multiples against the company's own last five fiscal years; analyst targets and ratings.
Multiples and returns
TTM vs 5 fiscal years| Now | 5y average | Where today sits in the 5-year range | |
|---|---|---|---|
| P/E (TTM) | 37.0× | 30.9× | 25.8× – 37.0× |
| EV / EBITDA | 21.3× | 18.4× | 14.6× – 22.1× |
| EV / Sales | 3.9× | 4.0× | 3.5× – 4.5× |
| Price / FCF | 20.0× | 24.4× | 17.6× – 35.4× |
| Price / Book | 264.4× | 385.0× | 108.3× – 1,183.4× |
| FCF yield | 5.0% | 4.3% | 2.8% – 5.7% |
| Return on invested capital | 30.1% | 25.4% | 22.4% – 30.6% |
| Return on equity | 1,135.8% | 1,297.9% | 355.7% – 3,948.1% |
Analysts
Consensus target $100.14 (+5.1%)
range $95.00 – $106.00 · rating Hold
Strong buy0
Buy18
Hold25
Sell2
Strong sell0
Outlook
Analyst consensus for the coming fiscal years and what it implies at today's price.
Consensus estimates
| Fiscal year | Revenue | Growth | EPS | Growth | P/E at today's price | Analysts (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $21.4B | +5.1% | $3.88 | +47.4% | 24.6× | 11 |
| FY2027 | $22B | +2.8% | $4.08 | +5.2% | 23.4× | 12 |
| FY2028 | $22.7B | +3.3% | $4.38 | +7.4% | 21.8× | 5 |
| FY2029 | $23.4B | +3.1% | $4.58 | +4.6% | 20.8× | 1 |
| FY2030 | $24.1B | +2.7% | $4.76 | +3.8% | 20.0× | 1 |
Financial statements
Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.
Every reported line
All 279 figures Colgate-Palmolive Company tagged in its recent 10-Q / 10-K filings, with the official SEC label and definition - including the notes (leases, taxes, buybacks, employees, ...).
| Line (SEC label) | Latest quarter | Year ago | y/y | Latest FY | Prior FY | y/y |
|---|---|---|---|---|---|---|
| $218M | – | – | – | – | – | |
| Accounts Payable, Current | $2.1B | $1.87B | +12.3% | $2.09B | $1.81B | +15.7% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $1.9B | $1.81B | +5.2% | $1.68B | $1.52B | +10.1% |
| Accounts Receivable, Allowance for Credit Loss, Current | $90M | $92M | -2.2% | $90M | $85M | +5.9% |
| Accrual for Taxes Other than Income Taxes, Current | $254M2025-12-31 | $162M | +56.8% | $254M | $162M | +56.8% |
| Accrued Income Taxes, Current | $358M | $339M | +5.6% | $383M | $403M | -5.0% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $6.48B | $6.29B | +3.1% | $6.2B | $5.71B | +8.6% |
| Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax | $587M | $586M | +0.2% | $583M | $605M | -3.6% |
| Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax | -$3.34B | -$3.36B | +0.6% | -$3.35B | -$3.69B | +9.1% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$3.87B | -$3.89B | +0.6% | -$3.88B | -$4.22B | +8.1% |
| Additional Paid in Capital | $4.47B | $4.28B | +4.4% | $4.32B | $4.18B | +3.4% |
| Advertising Expense | – | – | – | $2.7B | $2.72B | -0.6% |
| Amortization of Intangible Assets | – | – | – | $78M | $75M | +4.0% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 1.25M | 1.06M | +17.6% | 1.79M2013-12-31 | 3.5M | -49.1% |
| Assets | $16.7B | $17.5B | -4.4% | $16.3B | $16B | +1.8% |
| Assets, Current | $6.36B | $6.04B | +5.3% | $5.71B | $5.32B | +7.4% |
| Buildings and Improvements, Gross | $2.17B2025-12-31 | $2.06B | +5.6% | $2.17B | $2.06B | +5.6% |
| Cash and Cash Equivalents, at Carrying Value | $1.53B | $1.28B | +19.4% | $1.29B | $1.1B | +17.5% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $1.53B | $1.28B | +19.4% | $1.29B | $1.1B | +17.5% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $157M | $64M | +145.3% | $192M | $130M | +47.7% |
| Commitments and Contingencies | $02025-12-31 | $0 | – | $0 | $0 | – |
| Common Stock, Dividends, Per Share, Declared | $0.53 | $0.52 | +1.9% | $2.08 | $2.48 | -16.1% |
| Common Stock, Par or Stated Value Per Share | $1.00 | $1.00 | 0.0% | $1.00 | $1.00 | 0.0% |
| Common Stock, Shares Authorized | 2B | 2B | 0.0% | 2B | 2B | 0.0% |
| Common Stock, Shares, Issued | 1.47B | 1.47B | 0.0% | 1.47B | 1.47B | 0.0% |
| Common Stock, Shares, Outstanding | 801M2025-12-31 | 813M | -1.4% | 801M | 813M | -1.4% |
| Common Stock, Value, Issued | $1.47B | $1.47B | 0.0% | $1.47B | $1.47B | 0.0% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | $28M | $27M | +3.7% | $131M | $152M | -13.8% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $701M | $771M | -9.1% | $2.47B | $2.61B | -5.0% |
| Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | $729M | $798M | -8.6% | $2.61B | $2.76B | -5.5% |
| Cost of Revenue | $2.14B | $2.08B | +2.6% | $8.13B | $7.94B | +2.4% |
| Deferred Income Tax Assets, Net | $222M | $216M | +2.8% | $205M | $195M | +5.1% |
| Deferred Income Tax Expense (Benefit) | – | – | – | -$156M | -$33M | -372.7% |
| Deferred Income Tax Liabilities, Net | $262M | $304M | -13.8% | $181M | $343M | -47.2% |
| Deferred Income Taxes and Tax Credits | $69M | $25M | +176.0% | -$109M | -$77M | -41.6% |
| Deferred Other Tax Expense (Benefit) | – | – | – | -$49M | $8M | -712.5% |
| Deferred Tax Assets, Gross | $1.43B2025-12-31 | $1.33B | +7.4% | $1.43B | $1.33B | +7.4% |
| Deferred Tax Assets, in Process Research and Development | $132M2025-12-31 | $108M | +22.2% | $132M | $108M | +22.2% |
| Deferred Tax Assets, Net | $24M2025-12-31 | – | – | $24M | – | – |
| Deferred Tax Assets, Net of Valuation Allowance | $1B2025-12-31 | $1B | -0.4% | $1B | $1B | -0.4% |
| Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration | $6M2025-12-31 | $13M | -53.8% | $6M | $13M | -53.8% |
| Deferred Tax Assets, Other | $99M2025-12-31 | $101M | -2.0% | $99M | $101M | -2.0% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | $61M2025-12-31 | $61M | 0.0% | $61M | $61M | 0.0% |
| Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities | $266M2025-12-31 | $223M | +19.3% | $266M | $223M | +19.3% |
| Deferred Tax Assets, Valuation Allowance | $430M2025-12-31 | $328M | +31.1% | $430M | $328M | +31.1% |
| Deferred Tax Liabilities, Goodwill and Intangible Assets | $283M2025-12-31 | $389M | -27.2% | $283M | $389M | -27.2% |
| Deferred Tax Liabilities, Gross | $976M2025-12-31 | $1.15B | -15.3% | $976M | $1.15B | -15.3% |
| Deferred Tax Liabilities, Leasing Arrangements | $124M2025-12-31 | $126M | -1.6% | $124M | $126M | -1.6% |
| Deferred Tax Liabilities, Net | – | – | – | $148M2024-12-31 | $147M | +0.7% |
| Deferred Tax Liabilities, Other | $71M2025-12-31 | $130M | -45.4% | $71M | $130M | -45.4% |
| Deferred Tax Liabilities, Property, Plant and Equipment | $384M2025-12-31 | $397M | -3.3% | $384M | $397M | -3.3% |
| Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years | $1.19B2025-12-31 | $1.17B | +1.7% | $1.19B | $1.17B | +1.7% |
| Defined Benefit Plan, Expected Future Benefit Payment, Year Five | $250M2025-12-31 | $242M | +3.3% | $250M | $242M | +3.3% |
| Defined Benefit Plan, Expected Future Benefit Payment, Year Four | $250M2025-12-31 | $242M | +3.3% | $250M | $242M | +3.3% |
| Defined Benefit Plan, Expected Future Benefit Payment, Year One | $435M2025-12-31 | $471M | -7.6% | $435M | $471M | -7.6% |
| Defined Benefit Plan, Expected Future Benefit Payment, Year Three | $250M2025-12-31 | $241M | +3.7% | $250M | $241M | +3.7% |
| Defined Benefit Plan, Expected Future Benefit Payment, Year Two | $245M2025-12-31 | $238M | +2.9% | $245M | $238M | +2.9% |
| Depreciation, Depletion and Amortization | $159M | $158M | +0.6% | $630M | $605M | +4.1% |
| Derivative Asset | $30M | $22M | +36.4% | $18M | $33M | -45.5% |
| Derivative Asset, Current | $18M2025-12-31 | $33M | -45.5% | $18M | $33M | -45.5% |
Source: SEC companyfacts (XBRL of every 10-Q / 10-K). Cash-flow quarters are derived from the year-to-date figures the 10-Q tags. Segment breakdowns are tagged with dimensions and are shown in the segment section instead.
Sources
Statements, segment revenue, metrics, estimates: Financial Modeling Prep. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
Data as of 2026-11-01